주 메뉴 바로가기 본문 바로가기 하단 바로가기

Small Molecules

We develop new engines for our future growth by strengthening
our presence in the global Small Molecules market

Generic Celltrion Project

Overview

The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical market.

Business Strategy

Starting with Temixys, the first incrementally modified drug (IMD) for HIV to be approved by the United States FDA (2018), Celltrion is carrying out a strategy to take the lead in the global generic pharmaceutical market by entering the US and global tender markets, and building its global distribution network.

  • Secure presence in
    the global market
    • Develop IMDs and generic drugs
    • Enter the US and global tender markets
    • Perform initial clinical trials for new drugs
  • Acquire new portfolios and
    boost global sales
    • Carry out global clinical trials for new drugs
    • Secure 20 or more generic products in portfolio
    • Expand global distribution network
  • Become a global
    pharmaceutical company
    • Globally launch new drugs
    • Build a stable sales structure
    • Take the lead in the global generic pharmaceutical market

Business Competencies

  • World-class knowledge in development,
    clinical trial, and approval
    • World-class knowledge in development,
      clinical trials, and approvals
    • Cooperation and synergy with affiliate, CelltrionPharm, specializing in generic pharmaceutical production
  • Production and quality competencies
    recognized by leading regulators
    • First Korean company with production facilities certified by US FDA and UK MHRA
    • Capable of manufacturing five billion tablets per year
    • Operates a stable SCM encompassing production and distribution
  • R&D facilities specializing in
    generic pharmaceutical products
    • Runs a research center dedicated to generic pharmaceutical products
    • Continues to develop pipelines for IMDs, new chemical entities, and generic drugs
    • Researches platform technologies including drug delivery systems
    • Researches ways to improve production efficiency
Efficiency improved
through intra-group cooperation

For the success of the GCP, Celltrion Group has divided the tasks across two divisions. Celltrion Generic Business Division presides over the overall project, while Celltrion Pharm is responsible for research and production functions. The two organizations perform their respective tasks with expertise and work together to form a technical analysis body to identify candidate products and secure new portfolios.

Celltrion Celltrion Pharm
  • Planning
  • R&D
  • Process Development
  • Clinical Trial
  • Approval
  • Production
  • Distribution